Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:BEACON_trial
gptkb:Cotellic |
| gptkbp:activities |
MEK inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
gptkb:dabrafenib
|
| gptkbp:class |
gptkb:Cloud_Computing_Service
|
| gptkbp:clinical_trial |
Phase III
~50% |
| gptkbp:developed_by |
gptkb:Array_Bio_Pharma
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
2018-06-27
|
| https://www.w3.org/2000/01/rdf-schema#label |
binimetinib
|
| gptkbp:indication |
unresectable or metastatic melanoma
|
| gptkbp:ingredients |
C19 H19 N5 O3 S
|
| gptkbp:is_atype_of |
L01 X E34
|
| gptkbp:is_used_for |
treatment of melanoma
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
Mektovi
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash elevated liver enzymes |
| gptkbp:targets |
ME K1 and ME K2
|
| gptkbp:type_of |
1195760-54-4
|